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Abstract
Purpose of Review The ANRS 12249 treatment as prevention (TasP) trial investigated the impact of a universal test and treat
(UTT) approach on reducing HIV incidence in one of the regions of the world most severely affected by the HIV epidemic—
KwaZulu-Natal, South Africa. We summarize key findings from this trial as well as recent findings from controlled studies
conducted in the linked population cohort quantifying the long-term effects of expanding ART on directly measured HIV
incidence (2004–2017).
Recent Findings The ANRS TasP trial did not—and could not—demonstrate a reduction in HIV incidence, because the offer of
UTT in the intervention communities did not increase ART coverage and population viral suppression compared to the standard
of care in the control communities. Ten controlled studies from the linked population cohort—including several quasi-
experimental study designs—exploit heterogeneity in ART exposure to show a consistent and substantial impact of expanding
provision of ART and population viral suppression on reduction in HIV incidence at the couple, household, community, and
population levels.
Summary In this setting, all of the evidence from large, population-based studies (inclusive of the ANRS TasP trial) is remark-
ably coherent and consistent—i.e., higher ART coverage and population viral suppression were repeatedly associated with clear,
measurable decreases in HIV incidence. Thus, the expanded provision of ART has plausibly contributed in a major way toward
the dramatic 43% decline in population-level HIV incidence in this typical rural African population. The outcome of the ANRS
TasP trial constitutes a powerful null finding with important insights for overcoming implementation challenges in the population
delivery of ART. This finding does not imply lack of ARTeffectiveness in blocking onward transmission of HIV nor its inability
to reduce HIV incidence. Rather, it demonstrates that large increases in ART coverage over current levels will require health
systems innovations to attract people living with HIV in early stages of the disease to participate in HIV treatment. Such
innovations and new approaches are required for the true potential of UTT to be realized.
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Introduction
In 2018, approximately 38 million people worldwide were
living with HIV [1]. About 80% of people living with HIV
knew their status and nearly 80% of these people (23.3 mil-
lion) accessed antiretroviral therapy (ART), a threefold in-
crease from 2010. Despite the successful scale-up and access
to HIV testing and treatment, HIV incidence remains high in
many settings, with an estimated 1.7 million newly infected
people in 2018. In particular, Eastern and Southern Africa
remain the regions the most severely affected by the HIV
epidemic [1].
The results from the landmark HPTN 052 trial in 2011
unequivocally showed that immediate initiation of ART was
associated with a 96% reduction in HIV sexual transmission
in sero-discordant stable couples [2]. To provide empirical
evidence of the feasibility and effectiveness of a universal test
and treat (UTT) strategy on reducing HIV incidence at the
population level, four major community-based trials were ini-
tiated in Eastern and Southern Africa [3••, 4–6]. The first of
these trials, the ANRS 12249 treatment as prevention (TasP)
trial, was conducted in rural South Africa between 2012 and
2016 and offered home-based HIV testing and universal Art
regardless of CD4 count in the intervention communities [3••,
7]. Three additional trials, BCPP (Botswana Combination
Prevention Project) -Ya Tsie, PopART (Population Effects of
Antiretroviral Therapy to Reduce HIV Transmission-
HPTN071), and SEARCH (the Sustainable East Africa
Research in Community Health) trials, were initiated in
2013 and completed between 2017 and 2018. The BCPP trial
was a pair-matched community-randomized trial conducted in
30 communities and compared the standard of care in the
control clusters with a combination prevention package in
the intervention clusters (community mobilization,
community-wide home-based and mobile HIV testing,
targeted outreach testing men and women ≤ 25 years of age,
active tracing and linkage to care support, increased access to
male circumcision services, and expanded ART) [4]. PopART
was conducted in 21 communities in Zambia and South Africa
with three arms: Arm A: universal ART coupled with
combination prevention intervention (door-to-door rapid
HIV testing services, referral for voluntary medical male cir-
cumcision (VMMC) among uncircumcised HIV-negative
men and antenatal care among HIV-positive pregnant women,
screening and referral for tuberculosis (TB) and sexually
transmitted infections (STIs), condom promotion and distri-
bution) Arm B: ART provided according to local guidelines
with combination prevention intervention and Arm C: the
standard of care [5]. The SEARCH trial was a pair-matched
cluster-randomized trial in 32 communities in rural Uganda
and Kenya and included 2-week mobile, multi-disease, com-
munity health campaigns including rapid HIV testing, referral
to HIV care, and home-based testing in all communities (i.e.,
both control and intervention arms) at baseline. Thereafter, the
control communities received the standard of care (i.e., nation-
al guideline–restricted ART) while the intervention communi-
ties received annual repeat campaigns including HIV testing
coupled with universal ART [6].
The outcomes and results of these trials have been well
documented and described [8–13]. Briefly, two of the trials
were able to demonstrate some evidence of moderate reduc-
tion in HIV incidence in intervention communities relative to
the standard of care [4, 5]. In the BCPP, the HIVincidence was
approximately 30% lower in the intervention communities
(0.59 per 100 person-years vs. 0.92 per 100 person-years in
the control communities) [4]. In the PopART, the HIV inci-
dence in the arm which received combination prevention
packages with ART administered according to national treat-
ment guidelines (1.06 per 100 person-years) was 30% lower
than that in the control arm (1.55 per 100 person-years), but
there was no difference in the arm which received combina-
tion prevention packages in addition to universal ART (1.45
per 100 person-years) [5]. However, collectively, the four tri-
als were unable to demonstrate consistent and substantial pop-
ulation reductions in HIV incidence. Aside from issues such as
sexual mixing of populations which are clearly important [14],
the more fundamental reason for lack of consistency in these
findings is that many of the trials were unable induce a sub-
stantially higher ART coverage in intervention communities
over the duration of the trial.Without a strong gradient in ART
coverage across the trial arms, the causal effect of ART on
population incidence cannot be estimated. Achieving such a
coverage differential was made particularly difficult by the
rapidly evolving treatment guidelines over the course of the
trials (which resulted in control communities adopting the
treat-all approach in three of the four trials over the course
of participant follow-up) and in many cases due to exemplary
care packages being delivered in “control communities”.
Some of the trials (most notably SEARCH [6]) were highly
successful in initiating large numbers of patients onto ART in
both the intervention and control communities through an
innovative community-based testing approach [6].
The ANRS TasP trial was conducted in the KwaZulu-Natal
province of South Africa, a region considered bymany to be at
the epicentre of the HIV pandemic. The setting provides a
remarkable opportunity to study the long-term impacts of
ART scale-up on HIV incidence from within the same popu-
lation because it also includes a linked population-based co-
hort which has been running for over 14 years. The population
cohort is based on a very similarmodus operandi to the ANRS
TasP trial and uses the gold-standard approach of actively
enrolling and following up a complete population observing
individual HIV seroconversions in those who were initially
observed to be HIV-uninfected. Here, we summarize key de-
sign features and results from the ANRS TasP trial as well as
recent findings from ten controlled studies from the
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population-based cohort that directly quantified the long-term
effects of expanding ART on directly measured HIV inci-
dence. Several of the studies used strong quasi-experimental
designs (such as regression discontinuity and instrumental
variable designs), which, like randomized controlled trials,
can control for both observed and unobserved confounding.
Overview of the ANRS 12249 Cluster-Randomized
Trial
The design of the ANRS TasP trial has been described in detail
elsewhere [15, 16]. Briefly, the ANRS TasP trial evaluated the
hypothesis that home-based HIV testing coupled with an im-
mediate offer of ARTwould result in a decrease in population-
level HIV incidence in a hyperendemic rural population. This
hypothesis was tested in a two-arm cluster-randomized trial
implemented between March 2012 and June 2016. Eleven
control communities were offered ART according to standard
of care (initially CD4 counts ≤ 350 cells/ml and then <
500 cells/ml from Jan 2015) and 11 intervention communities
were offered ART regardless of CD4 count. The study was
80% powered to detect an overall 34% reduction in cumula-
tive HIV incidence, with an estimated incidence of 2.25% per
year in the control clusters over the trial period. The calcula-
tion explicitly considered the different lengths of follow-up
time in the clusters, loss to follow-up, and the likelihood of
re-testing of participants as well as the potential diluting ef-
fects of inter-cluster sexual mixing [15].
The ANRS TasP trial was the first of the four treatments
as prevention trials and incorporated some novel features
aimed at enhancing efficiency and delivery of the interven-
tion in at least four areas are highlighting here. Firstly,
other than expanded ART eligibility in the intervention
arm, the interventions and mode of delivery were identical
in both arms of the trial. In the later trials—BCPP,
SEARCH, and PopART [4–6]—the makeup of the inter-
ventions differed from the control arms in ways other than
just expanded ART eligibility, such that the trials evaluated
the impact of a combination of interventions versus the
standard of care rather than only the additional impact of
UTT on population-level HIV incidence. In other words,
these subsequent trials included additional or enhanced ser-
vices in the intervention arm, besides universal ART. In the
BCPP, these included enhanced community mobilization
and expanded health prevention/screening, including male
circumcision, distribution of condoms, and home-based
HIV testing as well as HIV testing in mobile units during
the community campaign [4]. In PopART study, specific
mobile activities in the community, health screening for TB
and STIs, and home-based HIV testing were offered in the
intervention arms [5] while the SEARCH trial provided
repeat annual community health campaigns or mobilization
(including HIV testing at mobile sites, home-based HIV
testing, and referral to HIV care) [6] for 3 years after the
services were offered once in all intervention and control
communities at baseline.
Secondly, the ANRS TasP trial (along with the SEARCH
trial) evaluated the primary endpoint of HIV incidence among
the whole trial population as opposed to a nested sub-sample
of individuals within each cluster. Thirdly, the ANRS TasP
trial used explicit linkage to records from the pre-existing
public sector ART and trial clinics to quantify trends in ART
coverage. This enabled robust calculation and comparison of
the ARTcoverage at baseline and over the course of the trial in
a way unaffected by the biases commonly associated with
treatment self-report. Finally, ART was provided to partici-
pants in trial-specific clinics located in each of the 22 clusters
at convenient locations. Many of the existing public sector
clinics required long travelling and waiting times to receive
treatment and care. Thus, trial clinics provided relatively easy
access to treatment as each trial participant lived within
45 min’ walk of the clinic in their respective clusters.
Results of the ANRS 12249 Cluster-Randomized Trial
During the trial period, 26,518 of 28,419 (93%) eligible indi-
viduals were contacted. Overall, there were 503 seroconver-
sions documented after 22,891 person-years of follow-up. The
trial team conducted testing and follow-up for an average of
2.3 years in each cluster. Over the course of the trial, the
incidence in the control clusters was almost identical to the
incidence that had been assumed in the sample size calcula-
tions, but did not differ significantly across the two arms: 2.11
per 100 person-years (95% CI 1.84–2.39) in the intervention
arm versus 2.27 per 100 person-years in the control arm (95%
CI 2.00–2.54) (adjusted hazard ratio 1.01, 95%CI 0.87–1.17).
During the trial, more than 90% of HIV-positive individuals
became aware of their diagnosis. However, at the end of the
trial, there were no significant differences in both ART cover-
age and population viral suppression between the intervention
and control communities. At the end of the trial, ART cover-
age was 52.8% in the control communities versus 53.4% in
the intervention communities [3••]. Similarly, population
levels of viral suppression were 46.2% versus 44.2% in the
intervention versus control communities, from the baseline of
23.5% and 26.0%, respectively [17].
Key Insights from the ANRS 12249
Cluster-Randomized Trial
The outcome of this well-conducted trial constitutes a power-
ful null finding with important lessons for overcoming chal-
lenges in the population delivery of ART. We highlight three
key insights below. Firstly, the concern by participants about
inadvertent disclosure of HIV status by attending one of the
trial clinics likely contributed to the relatively poor linkage to
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care observed in the trial. Poor linkage to care was associated
with being newly diagnosed with HIV, being students, living
farther away from the clinics, or having higher educational
attainment [18, 19]. The results brought into sharp focus the
continued stigma around HIVand highlighted the critical need
to normalize its treatment. A typical quote from a participant
in this trial illustrates this point:
There are those who are still not keen [to attend the TasP
clinic]. They have a problem that they will be seen at the
park home [TasP clinic] and they say that the park home
is full of people who have HIV. You see it is something
like that. You see there are people who go to the clinic
not because they are going to check their own illnesses
but they keep looking at the people who are going to the
research clinic and they say we are even carrying babies
who have HIV. Now when a lot of people think about
that they think if you go to that clinic you are visible,
they wish they can hide from others. (Female, 51 years)
In this vein, the SEARCH trial model (described in detail
elsewhere [20]) of taking a community-based, multi-disease
approach for the management and treatment of HIV would
seem to hold considerable promise.
Secondly, the contact rate was significantly lower in
men and younger individuals [3••, 21]; however, among
those who received the community intervention, linkage
to care was similar in both men and women [18]. It is
therefore vital that novel methods are found to engage
men and younger populations to facilitate increased and
more rapid linkage to treatment and care. In response to
these findings, a 2 × 2 factorial cluster-randomized com-
munity-based trial, Home-Based Intervention to Test and
Start (HITS) [22], was initiated in the AHRI population
cohort [22, 23]. The HITS trial aims to establish the
impact of small once-off financial incentives and a
male-targeted HIV-specific decision support application
on improving the uptake of HIV testing and linkage to
care among men, with the ultimate aim of reducing
population-level HIV incidence in (particularly young)
women. Thus far, the HITS trial has demonstrated that
a once-off financial micro-incentive of just $3 increased
the uptake of HIV testing more than 50% among men
[24].
Thirdly, the ANRS TasP trial identified individuals earlier
in the course of their HIV infection, the majority of whom
were asymptomatic. Competing priorities between livelihood
sustenance, as seen by the high prevalence of food insecurity
[25] in the trial population and time required to seek care,
meant HIV-positive individuals likely delayed starting ART.
Studies which have highlighted the individual benefits of ear-
ly ART [26, 27] and differentiated models of care, including
same-day [28] and community provision of ART [29], could
alleviate the burden of seeking ART, thus allowing patients to
initiate treatment earlier potentially while in the acute phase of
infection [30–32].
Overview of the AHRI Population-Based Cohort
Since 2004, AHRI has conducted annual population-based
HIV testing among all consenting adults aged 15 years or
older in a community immediately adjacent to the ANRS
TasP trial area [23]. The AHRI cohort constitutes one of the
world’s largest population-based longitudinal HIV cohorts
and has measured the population trends in directly measured
HIV incidence and quantified important socio-demographic,
behavioural, and contextual determinants of newly acquired
HIV infections [23]. Both the ANRS TasP trial and the AHRI
population-based cohort share a very similar modus operandi
based on the gold-standard approach of actively enrolling and
following up a complete population and observing individual
HIV seroconversions in those participants who were initially
observed to be HIV-uninfected. The main difference between
the two cohorts is that the AHRI population cohort conducts
annual home-based testing, whereas the ANRS TasP trial con-
ducted testing at 6-month intervals. The other major difference
is that the period of follow-up is longer in the AHRI popula-
tion cohort (> 14 years versus an average of 2.3 years in the
ANRS TasP trial), encompassing the full period of ARTscale-
up.
A major strength of population-based cohorts that have
enrolled and prospectively followed complete populations
over decades is that representative knowledge (both with re-
spect to disease outcomes but also on a dynamic suite of
socio-demographic-, societal-, and community-level risk fac-
tors) is gained on all participants over time irrespective of
whether individuals attend care. Such designs provide a strong
basis for causal inference as well as a good standpoint from
which to quantify the population-level impacts of interven-
tions. The findings are therefore not subject to many of the
biases commonly inherent in clinical studies based on patients
who choose (and are able) to attend clinic or on a pre-selected
sample of individuals who might differ from the population in
ways that are difficult to evaluate. Moreover, because changes
in measures like household wealth and sexual behaviour are
systematically measured over time for each individual, it
means that these measures can be used to explicitly rule out
alternative explanations of the relationships observed, and that
any findings are not subject to the pitfalls of ecological fallacy.
The rich data measured in these population-based studies have
high external validity which also provides opportunities for
quasi-experimental study designs, such as regression discon-
tinuity and instrumental variable designs, to control for all
unobserved confounding [33•, 34]. In the same way that the
ongoing population-based cohorts like the Framingham Heart
Study have been able to generate important insights into the
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underlying risk factors for cardio-vascular disease [35], so too
have ongoing population cohorts such as the AHRI cohort in
South Africa [23] and the Rakai cohort in Uganda [36, 37]
generated profound epidemiological insights into the risk fac-
tors, trajectory of epidemics, mechanisms and underlying
causal risk factors, and pathways to HIV acquisition.
By the end of 2017, the AHRI population-based cohort
contained ~ 105, 000 person-years of observation and ~
3500 directly observed HIV seroconversions [38]. These large
sample sizes taken from a complete population followed lon-
gitudinally for well over a decade permit powerful statistical
inference. This in turn can facilitate a deep and nuanced un-
derstanding of underlying causal risk factors and processes
and a quantification of dynamic incidence patterns among
different population sub-strata allowing for identification of
particularly vulnerable sub-groups [39–42].
Key Findings from the AHRI Population-Based Cohort
Figure 1 (accompanied by a more detailed description in
Table 1) summarizes the ANRS TasP trial results [3••] as well
as ten recent, controlled studies from the ongoing population-
based cohort [38, 43•, 44••, 45–50]. These studies have me-
ticulously quantified the real-world, long-term impacts of
expanding ART provision on reduction in risk of new HIV
infection across communities [44••, 45], within households
[46, 47], within couples [49], and across the general popula-
tion [38, 43•, 48]. One recent study also quantified the risk of
expansion of ART provision on newly diagnosed TB infection
[50]. In the population-based cohort, the duration of follow-up
encompasses the period immediately both before and after the
scale-up of ART, allowing for strong experimental separation
among different population sub-groups in respect of ART ex-
posure (i.e., large differences in ARTcoverage). These studies
have exploited this heterogeneity in ART exposure and viral
suppression across individuals and communities, within cou-
ples and households, and over time and space, for robust caus-
al inference. Using this variation, the studies demonstrate con-
sistently strong evidence for the preventative benefits of ART,
using diverse methods and statistical models and explicitly
controlling for well-known predictors of HIV incidence
(Fig. 1, Table 1).
Fig. 1 Summary of findings of the ANRS 12249 cluster-randomized trial
(most left-hand point [3••]) as well as the results of ten controlled studies
from the ongoing AHRI longitudinal population cohort [38, 43•, 44••,
45–50]. Both the ANRS TasP trial and the ongoing population-based
cohort follow a similar modus operandi and utilize the gold-standard
approach of enrolling and actively following up a complete population
over time and directly measuring individual HIV seroconversions in those
individuals who are initially observed to be HIV-uninfected. The studies
in the population cohort have quantified the real-world, long-term
impacts of expanding ART provision on reduction HIV incidence (and
incidence-derived metrics) [38, 43•, 44••, 45–49]. One study also
quantified the risk of expanding ART provision on newly diagnosed TB
infection [50]. Further details of these studies are provided in Table 1. The
studies utilize one of the world’s largest ongoing population-based
cohorts that has measured the socio-demographic, behavioural, and
contextual determinants of HIV incidence as well as the population
trends over >14 years. The duration of follow-up of the population
cohort encompasses the period both immediately before and after the
scale-up of ART allowing for strong experimental separation in ART
exposure (i.e., large differences in ART coverage) across time and
space, within (and across) couples and households, as well as between
different population sub-groups. The studies include quasi-experimental
designs, such as regression discontinuity and instrumental variable
designs
Curr HIV/AIDS Rep (2020) 17:97–108 101
Table 1 Summary of findings of the ANRS 12249 cluster-randomized trial as well as the results of 10 recently published controlled studies from the
ongoing longitudinal population cohort (in order of ascending date).
Study Period and
participants
Objectives Results Sample size (N);
effect estimate (95%
CI); P value
Differential in ART
coverage or other
indicators
Conclusion
Tanser et al.
[44••]
2004–2011;
women
aged
15–-
49 years,
men aged
15–-
54 years
To measure the effect of
community-level
ARTcoverage onHIV
incidence, controlling
for multiple
socio-demographic,
behavioural, and
community variables.
An HIV-uninfected
individual living in a
community with high
ART coverage (30 to
40% of all
HIV-infected
individuals on ART)
was 37% less likely to
acquire HIV than
someone living in a
community where
ART coverage was
low (< 10% of all
HIV-infected
individuals on ART).
N = 16,667;
aHR = 0.63
(0.44–0.91);
P = 0.013
30–40% vs. < 10% Population-level
reductions in the
transmission of HIV
can be achieved in
nurse-led, devolved,
public-sector ART
programs in rural
sub-Saharan African
settings where
complete coverage of
therapy under existing
treatment guidelines
has not yet been
attained.
Vandormael
et al. [46]
2004–2012;
women
aged
15–-
49 years,
men aged
15–-
54 years
To measure the effect of
ART usage in the
household on HIV
incidence, controlling
for multiple
socio-demographic,
behavioural, and
community variables.
An HIV-uninfected
individual living in a
household with high
opposite-sex ART
coverage (50 to 60%)
was 26% less likely to
acquire HIV than
someone living in a
household with a low
opposite-sex ART
coverage (< 10%).
N = 14,505;
aHR = 0.74
(0.61–0.91);
P < 0.05
50–60% vs. < 10% Results provide further
evidence that ART
significantly reduces
the risk of onward
transmission of HIV
in a real-world setting.
Awareness that ART
can prevent
transmission to
co-resident sexual
partners could be a
powerful motivator
for HIV testing and
ART uptake,
retention, and
adherence.
Wirth et al.
[45]
2004–2011;
women
aged
15–-
49 years,
men aged
15–-
54 years
To evaluate the impact of
community ART
coverage on HIV
incidence risk using
an instrumental
variable (IV)
approach. The IV
approach was used to
account for the
possibility that
individuals living in
high ART coverage
areas may
systematically differ
from those in low
ART coverage areas
even after controlling
for multiple predictors
of infection.
In the IV-adjusted model,
persons in
communities with
> 40% ART coverage
were 62% less likely
to acquire HIV
infection than persons
in communities with
< 10% ART coverage.
Person-years = 53,605;
aHR = 0.38
(0.17–0.84);
P < 0.001
> 40% vs. < 10% The findings indicate that
the effect of
community-level
ARTcoverage on HIV
incidence was not
only robust to
unmeasured
confounding but may
be stronger than
previously reported in
Tanser et al. [44••]
Oldenburg
et al. [49]
2005–2013;
women
and men
aged
> 15 years
To evaluate the
preventative impact of
ART on HIV
incidence in stable
sero-discordant
couples, controlling
for multiple
socio-demographic,
behavioural, and
community variables.
Use of ARTwas
associated with a 77%
decrease in HIV
incidence risk among
sero-discordant
couples.
N = 17,016 and
n = 2042
(discordant
couples);
aHR = 0.23
(0.07–0.80);
P = 0.02
On ART vs. not on ART ART initiation was
associated with a large
reduction in HIV
incidence in
sero-discordant
couples in rural
KwaZulu-Natal.
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Table 1 (continued)
Study Period and
participants
Objectives Results Sample size (N);
effect estimate (95%
CI); P value
Differential in ART
coverage or other
indicators
Conclusion
Tanser et al.
[48]
2011–2015;
women
aged
15–-
49 years,
men aged
15–-
54 years
To empirically quantify
the relationship
between a range of
population viral load
(PVL) measures and
the prospective risk of
HIV incidence among
participants who were
HIV-negative at
baseline. Analyses
were controlled for
multiple
socio-demographic,
behavioural, and
community variables.
Prospective HIV
incidence in
communities where
the population
prevalence of
detectable viremia in
the 1st quartile
(< 12%) was 37%
lower compared to
communities in the
4th quartile (> 19%).
N = 8732; aHR = 0.63
(0.52–0.77);
P < 0.001
Population prevalence
of detectable viremia
> 19% (4th quantile)
vs. 12% (1st
quantile)
Results show a clear
relationship between
PVLmeasures such as
the population
prevalence of
detectable viremia and
prospective incidence
of HIV infection. PVL
indices could play a
key role in targeting
and monitoring
interventions in the
most vulnerable
communities where
the future rate of new
HIV infections is
likely to be highest.
Iwuji et al.
[3••]
2012–2016;
resident
men and
women
aged
> 16 years
To investigate the effect
of universal test and
treat on HIVincidence
using a
cluster-randomized
trial. The intervention
group received
immediate ART
initiation upon HIV
diagnosis. The control
group had ART
initiation at CD4 T
cell counts < 350 and
< 500 cells/μl upon
HIV diagnosis
(following national
eligibility guidelines).
HIV incidence was 2.11
per 100 person-years
(95%CI 1.84–2.39) in
the intervention group
and 2.27 per 100
person-years
(2.00–2.54) in the
control group.
N = 26,518;
aHR = 1.01
(0.87–1.17); P = 0.89
45% ART coverage (in
the treatment group)
vs. 43% (in the
control group)
There was no difference
in HIV incidence
between the
intervention and
control groups.
Absence of a lowering
of HIV incidence in
universal test and treat
clusters occurred as a
consequence of there
being no difference in
ART coverage and
population-level viral
suppression between
control and
intervention
communities.
Oldenburg
et al. [47]
2007–2011,
women
and men
aged
> 15 years
To investigate the effect
of immediate vs.
delayed ART on HIV
incidence among
household members.
The study used a
quasi-experimental
approach (regression
discontinuity), which
is designed to improve
causal inference in
nonrandomized
studies.
Compared with delayed
ART initiation,
immediate initiation
reduced HIV
incidence in
households by 47%
and by 32–60% in
alternate
specifications of the
model.
N = 4115; aHR = 0.53
(0.30–0.96);
P < 0.05
Threshold of 200 CD4+
count cell/μl used to
determine immediate
vs. delayed initiation
This study demonstrates
for the first time
causally some of the
spill-over effects that
contribute to the
population impact of
HIV treatment on HIV
incidence.
Vandormael
et al. [38]
2005–2017;
women
aged
15–-
49 years,
men aged
15–-
54 years
To quantify trends in the
incidence to mortality
ratio (IMR) between
2005 and 2017. The
UNAIDS has
proposed IMR as a
key measure of
epidemic control [51].
Epidemic control is
achieved when the
ratio of new infections
to the number of
all-cause HIV-related
deaths falls below 1.
The observed IMR
peaked at 5.74 in 2013
before declining to
4.06 in 2017.
Bootstrapped
estimates show an
IMR reduction of
25% during this
period.
N = 22,758 (HIV−
cohort) and
N = 13,460 (HIV+
cohort); IMR = 0.75
(0.69–0.85);
P < 0.05
ARTcoverage increased
from 2% in 2005
(CD4+ count
< 200 cells/μl) to
30% in 2011
(< 350 cells/μl) to
47% in 2016 (all
eligible) and to 46%
in 2017.
The results show
impressive progress
toward HIV epidemic
control in the study
area. However, the
IMR epidemic
threshold < 1 was not
reached in 2017.
Progress is off track
for 2020 targets set by
the UNAIDS.
Vandormael
et al. [38]
2005–2017;
women
To quantify trends in the
incidence to
The IPR declined from
0.144 in 2012 to 0.075
N = 39,735 (HIV
prevalence);
ARTcoverage increased
from 2% in 2005
The decline in this metric
indicates further
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For example, the first study from the population cohort
quantifying the treatment as prevention effect found that a
1% increase in ART coverage in the surrounding community
is independently associated with an average 1.4% decline in
an individual’s risk of acquisition of HIV infection (adjusted
hazard ratio (aHR) = 0.986) [44••]. The results of the study
and implications for treatment as prevention at the time are
discussed in two commentaries [52, 53]. Other findings from
this population cohort demonstrate, for example, that within
sero-discordant couples, use of ART is associated with a 77%
decrease in HIV incidence [49]. Within households, an HIV-
uninfected individual in a household characterized by high
opposite-sex ART coverage is 26% less likely to acquire
HIV than someone living in a household with a low
opposite-sex ART coverage [46] and compared with delayed
ART initiation, immediate initiation of ART reduced HIV in-
cidence in households by 47% [47]. At a community-level,
every 1% increase in the proportion of an entire community
Table 1 (continued)
Study Period and
participants
Objectives Results Sample size (N);
effect estimate (95%
CI); P value
Differential in ART
coverage or other
indicators
Conclusion
aged
15–-
49 years,
men aged
15–-
54 years
prevalence ratio (IPR)
between 2005 and
2017. The IPR is
another metric of HIV
epidemic control
proposed by
UNAIDS. Epidemic
control is achieved
when there is less than
one new HIV
infection over a
33-year period on
ART. The average
survival time of a
newly infected person
on ART is 33 years,
which translates into
1/33 or 3 new
infections per 100
people living with
HIV per year.[51]
in 2017. Bootstrapped
estimates show an IPR
reduction of 54%
during this period.
N = 22,758 (HIV−
cohort) IPR = 0.46
(0.34–0.62);
P < 0.05
(CD4+ count
< 200 cells/μl) to
30% in 2011 (< 350
cells/μl) to 47% in
2016 (all eligible)
and to 46% in 2017.
progress toward HIV
epidemic control in
the study area.
However, the
epidemic threshold of
< 0.03 was not
reached in 2017.
Progress is off track
for 2020 targets set by
the UNAIDS.
Tomita et al.
[50]
2009–2015;
men and
women
aged
> 15 years
To quantify the impact of
community coverage
of ART on recently
diagnosed TB disease,
controlling for
multiple
socio-demographic,
behavioural, and
community variables.
Living in a community
with ART coverage
≥ 50% was associated
with a 34% decrease
in the odds of recently
diagnosed TB vs.
living in a community
with ART coverage
< 50%.
N = 41,812;
aOR = 0.66
(0.49–0.88);
P = 0.005
ARTcoverage ≥50% vs.
< 50%
Results indicate the
potential benefit of
increased community
ART coverage in
lowering the risk of
active tuberculosis
highlighting the need
to prioritize the
expansion of such
effective population
interventions targeting
high-risk areas.
Vandormael
et al.
[43•]
2005–2017;
women
aged
15–-
49 years,
men aged
15–-
54 years
To quantify trends in the
population-wide HIV
incidence following
ART scale-up,
controlling for
multiple
socio-demographic,
behavioural, and
community variables.
The HIV incidence rate
declined from 3.94
(95%CI 3.37–4.60) to
2.25 (1.79–2.83)
events per 100
person-years between
2012 and 2017—a
reduction of 43%.
N = 22,239;
IRR= 0.57
(0.43–0.75);
P < 0.001
ARTcoverage increased
from 2% in 2005
(CD4+ count
< 200 cells/μl) to
30% in 2011
(< 350 cells/μl) to
47% in 2016 (all
eligible) and to 46%
in 2017.
The study shows robust
evidence of large HIV
incidence declines
among men and
women, which are
consistent with the
scale-up of ART and
VMMC services.
ART, antiretroviral therapy; aHR, adjusted hazard ratio; aOR, adjusted odds ratio; IV, instrumental variable; IMR, incidence to mortality ratio; IPR,
incidence to prevalence ratio; IRR, incidence rate ratio; VMMC, voluntary medical male circumcision
These studies have quantified the real-world, long-term impacts of expanding ART provision on reduction in risk of new HIV infection across different
communities, within households, within sero-discordant couples, and in the general population
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having a detectable virus is independently associated with a
6.3% prospective increase in risk of HIVacquisition for HIV-
negative individuals living in that community [48].
At a population level, overall HIV incidence between 2012
and 2017 declined dramatically by 43% (Fig. 2) [43•].
Consistent with treatment as prevention playing a major role
in this population-level reduction, HIV incidence declined
among both circumcised and uncircumcised men. Moreover,
men experienced earlier and larger HIV incidence declines
than women, consistent with higher ARTcoverage in women.
Specifically, male incidence declined by 59%, from 2.5 to 1.0
sero-conversion events per 100 person-years, which coincided
with female ART coverage surpassing 35% in 2012 and
VMMC scale-up in 2009. There was a 37% reduction in fe-
male HIV incidence between 2014 and 2017, from 4.9 to 3.1
sero-conversion events per 100 person-years, which occurred
after male ART coverage reached 35% [43•]. While overall
progress is off track to meet the 2020 reduction targets set by
the UNAIDS [51], a recent paper documented impressive
progress toward HIV epidemic control in this population
[38]. Among men, the incidence to mortality ratio peaked at
4.1 in 2013 before dropping to 3.1 in 2017 (a 24% reduction)
while the female incidence to mortality ratio climbed to as
high as 6.4 in 2013 before dropping to 4.3 in 2017 (a 33%
reduction). Between 2012 and 2017, the male-incidence to
female-prevalence ratio declined from 0.05 to 0.02.
Compared with men, however, the female-incidence to
male-prevalence ratio was markedly higher and fell from
0.24 to 0.13 during the same period [38]. This result, when
coupled with the higher HIV incidence, incidence to mortality
ratio, and HIV prevalence among women, confirms the dis-
proportionate burden of HIV being experienced by women
relative to men in sub-Saharan Africa. Treatment for HIV is
also associated with secondary preventative benefits for TB
infection and shows a 34% reduction in the risk of newly
diagnosed TB infection to an individual living in a community
with ≥ 50% ART coverage (adjusted odds ratio (aOR) = 0.66,
95% CI 0.49–0.88) [50].
The results of these studies (Table 1, Fig. 1) are epidemio-
logically plausible and clear, measurable reductions in HIV
incidence and incidence-derived metrics were consistently
found across all studies. The findings were robust to different
model specifications, different age-eligibility criteria, differing
methods of constructing “communities,” and the inclusion of
differing control variables (including being robust to changes
in sexual behaviour, for example). Further, methods to impute
the date of HIV seroconversion were systematically investigat-
ed and the results were found to be robust to participant self-
selection associated with missed test dates and drop-out [54,
55]. It is thus unlikely that any collection of systematic biases
could consistently and simultaneously explain the findings
across the different studies conducted within households, cou-
ples, communities, population sub-groups, genders, and using
differing outcome metrics (and in one case, the outcome of a
different disease—i.e., newly diagnosed TB infection).
Nevertheless, the possibility of the existence of such a perva-
sive unidirectional residual confounding effect—however un-
likely—should be acknowledged. To rule out the possibility of
residual confounding, two quasi-experimental study designs
[45, 47] were implemented using instrumental variable (IV)
and regression discontinuity (RD) designs (Table 1). They do
this by quasi-randomly assigning individuals to intervention
vs. control groups, leveraging randomness induced by policy,
practice, or natural events [56–61]. The quasi-experimental
studies [45, 47] confirmed a large real-world treatment as pre-
vention effect that could not have been explained by the influ-
ence of any observed or unobserved factors. The Wirth et al.
[45] analysis not only confirmed the previous findings (and
therefore demonstrated that the result was robust to the effect
of unmeasured confounding) but also suggested that the effect
of community-level ART coverage on HIV incidence may be
even greater than previously estimated in the paper published
in Science [44••].
Conclusion
All of the evidence from large, population-based studies (in-
clusive of the ANRS TasP trial) in this setting is remarkably
consistent—i.e., higher ART coverage and population viral
suppression were repeatedly associatedwith large, measurable
Fig. 2 Population trends in HIV incidence with 95% confidence intervals
(CIs) between 2005 and 2017 in the AHRI population cohort. Male and
female HIV incidence declined substantially after 2012 and 2014,
respectively, with an overall population decline of 43% between 2012
and 2017. Reproduced from Vandormael et al. (2019) [43•] under a
creative commons licence (http://creativecommons.org/licenses/by/4.0/)
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decreases in HIV incidence. Despite increases in population
levels of viral suppression in both arms, the offer of UTT in
ANRS TasP trial did not induce differences in viral suppres-
sion between intervention and control communities and thus
the trial could not demonstrate a relative reduction in HIV
incidence in the intervention communities. As one of the
world’s largest ongoing HIV incidence cohorts and spanning
the period both immediately before and after the scale-up of
antiretroviral therapy, the AHRI population cohort allowed for
strong experimental separation in ART exposure (i.e., large
differences in ART coverage) and viral suppression between
different population sub-groups. The studies summarized in
this commentary exploited this heterogeneity in ART expo-
sure across individuals and communities, within couples and
households, and over time and space, for a robust quantifica-
tion of the treatment as prevention effect in a real-life setting.
In summary, the recent evidence from controlled,
population-based studies in this typical rural African popula-
tion demonstrates that expanded provision of ART has sub-
stantially and consistently reduced the risk of onward trans-
mission at multiple levels, which has plausibly contributed in
a major way toward the dramatic 43% decline in population-
level HIV incidence. Going forward, however, the incremental
gains in incidence reduction are likely going to be harder to
achieve. The outcome of the ANRS TasP trial constitutes a
powerful null finding with important lessons for overcoming
implementation challenges in the population delivery of ART.
This finding does not imply lack of ART effectiveness in
preventing the onward transmission of HIV nor the inability
to reduce population-level HIV incidence. Rather, it demon-
strates that large increases in ARTcoverage over current levels
will require health systems innovations to attract people living
with HIV in early stages of the disease to participate in HIV
treatment. Such innovations and new approaches are required
for the true potential of UTT to be realized. Attaining epidem-
ic control will require overcoming existing implementation
barriers to the continued expansion of ART accompanied by
the provision of other primary prevention measures.
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